| Cover | Nov. 13, 2024 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Nov. 13, 2024 |
| Entity File Number | 001-40536 |
| Entity Registrant Name | Acurx Pharmaceuticals, Inc. |
| Entity Central Index Key | 0001736243 |
| Entity Tax Identification Number | 82-3733567 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 259 Liberty Avenue |
| Entity Address, City or Town | Staten Island |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10305 |
| City Area Code | 917 |
| Local Phone Number | 533-1469 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | ACXP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
